Loading
Life sciences · Journal article
International Journal of Innovative Technologies in Social Science · October 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed and approved for the treatment of type 2 diabetes and obesity, are now demonstrating unprecedented therapeutic potential that extends beyond metabolic regulation alone. This review article aims to provide a comprehensive summary and analysis of the current state of knowledge regarding the expanding clinical horizons of GLP-1RAs, with a particular focus on their neuroprotective properties in Alzheimer’s disease (AD) and their use in the treatment of substance use disorders (SUDs), including alcohol dependence. Based on a systematic review of selected literature, including the latest preclinical studies and clinical trials, the multifaceted mechanisms of GLP-1 action in the central nervous system were analyzed. The accumulated evidence indicates that GLP-1 receptor agonists (GLP-1RAs) effectively cross the blood-brain barrier, alleviate systemic and local neuroinflammation, reduce oxidative stress, and improve synaptic plasticity. These effects translate into a halt in neuronal degeneration and beneficial cognitive outcomes in patients with early symptoms of AD. Furthermore, these drugs have been shown to innovatively modulate reward pathways in the brain (including the dopaminergic system), effectively reducing drug cravings, compulsive behaviors, and the consumption of alcohol and other addictive substances. In summary, the repurposing of GLP-1 receptor agonists represents an extremely promising strategy for treating complex neurological and psychiatric disorders. However, further large-scale clinical trials are necessary to optimize dosing protocols and confirm the long-term safety profile.